Long-term trends in the prescription of antidiabetic drugs: real-world evidence from the Diabetes Registry Tyrol 2012-2018
Long-term trends in the prescription of antidiabetic drugs: real-world evidence from the Diabetes Registry Tyrol 2012-2018
复制标题
DOI：
10.1136/bmjdrc-2020-001279
复制
发表时间：
2020-01-01
影响因子：
4.1
通讯作者：
Ebenbichler, Christoph
中科院分区：
文献类型：
--
作者：
Engler, Clemens;Leo, Marco;Ebenbichler, Christoph
根据糖尿病登记表TYROL，对2012-2018年期间抗糖尿病药物的处方模式进行调查。为了验证研究结果，我们将不同国家登记的数据与在可比时间段内进行的趋势进行了比较。研究设计和方法对2012年至2018年10 875例2型糖尿病患者的用药数据、处方模式、年龄组、抗糖尿病治疗和质量参数(血红蛋白A1c、体重指数、并发症)进行了回顾评估和描述性分析。结果钠/葡萄糖共转运体2抑制剂(SGLT-2i)的处方数在2012-2018年间显著增加(p<0.05)。
Introduction Prescription patterns of antidiabetic drugs in the period from 2012 to 2018 were investigated based on the Diabetes Registry Tyrol. To validate the findings, we compared the numbers with trends of different national registries conducted in a comparable period of time.Research design and methods Medication data, prescription patterns, age groups, antidiabetic therapies and quality parameters (hemoglobin A1c, body mass index, complications) of 10 875 patients with type 2 diabetes from 2012 to 2018 were retrospectively assessed and descriptively analyzed. The changes were assessed using a time series analysis with linear regression and prescription trends were plotted over time.Results Sodium/glucose cotransporter 2 inhibitors (SGLT-2i) showed a significant increase in prescription from 2012 to 2018 (p